title: Epinephrine-induced reversal of verapamil's electrophysiologic and therapeutic effects in patients with paroxysmal supraventricular tachycardia.
abstract: The purpose of our study was to determine whether an infusion of epinephrine reverses the electrophysiologic effects of verapamil and whether reversal of verapamil's effects on the induction of paroxysmal supraventricular tachycardia (PSVT) by epinephrine during electropharmacologic testing is predictive of stress-related recurrences of PSVT during long-term treatment with verapamil. The infusion rates of epinephrine used in this study were 25 and 50 ng/kg/min, which previously have been demonstrated to result in plasma epinephrine concentrations in the range that occurs during a variety of stresses in humans. The subjects of this study were 17 patients with recurrent PSVT who underwent an electrophysiologic study in the control state and after at least 2 days of treatment with 240-480 mg/day verapamil. After assessing the response to verapamil, epinephrine was infused and testing was repeated. Verapamil significantly slowed atrioventricular conduction and prolonged refractoriness in the atrium and atrioventricular node. The effects of the two infusion rates of epinephrine were generally similar in magnitude and, therefore, the results were pooled. Epinephrine partially or completely reversed all of verapamil's electrophysiologic effects. Verapamil suppressed the induction of sustained PSVT in 15 patients. Epinephrine facilitated the induction of PSVT in seven of these 15 patients. All 15 patients were treated on a long-term basis with verapamil. The eight patients in whom epinephrine did not facilitate the induction of PSVT had no recurrences of PSVT during 9-18 months of follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Division of Cardiology, University of Michigan Medical Center, Ann Arbor.
authors.forename: F
authors.initials: F
authors.lastname: Morady
authors.forename: W H
authors.initials: WH
authors.lastname: Kou
authors.forename: A H
authors.initials: AH
authors.lastname: Kadish
authors.forename: L K
authors.initials: LK
authors.lastname: Toivonen
authors.forename: J A
authors.initials: JA
authors.lastname: Kushner
authors.forename: S
authors.initials: S
authors.lastname: Schmaltz
mesh_terms: D001262:Atenolol / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial; D004594:Electrophysiology; D004837:Epinephrine / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013312:Stress, Physiological / Q000503:physiopathology; D013614:Tachycardia, Paroxysmal / Q000175:diagnosis / Q000188:drug therapy*; D013617:Tachycardia, Supraventricular / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors; D014700:Verapamil / Q000037:antagonists & inhibitors* / Q000627:therapeutic use
chemical_list: D001262:Atenolol; D014700:Verapamil; D004837:Epinephrine